Archive · 4 Nov 2025
Atorvastatin Recalled by FDA Due to Dissolution Issues
Imagine a pill that helps keep your heart healthy by cleaning out 'icky' stuff in your blood.
This special pill is called Atorvastatin.
Recently, a lot of these pills were called back because they weren't dissolving right.
When a pill doesn't dissolve properly, your body can't use all of its helpful medicine.
This means the pills might not work as well to protect you from heart attacks or strokes.
The good news is that the chances of getting really sick from these recalled pills are very small.
Doctors and pharmacists are working to make sure everyone gets the right medicine to keep their hearts strong.
Over 140,000 bottles of Atorvastatin, a statin drug used to fight heart disease, have been recalled by Ascend Laboratories.
The recall is due to the medication failing "dissolution specifications," meaning the tablets may not dissolve properly in the body.
If the tablets don't dissolve, the active ingredient may not be absorbed effectively, potentially making the drug less effective in lowering cholesterol.
The FDA warned that the recalled medication could cause temporary or medically reversible adverse health consequences, but serious risks are considered remote.
Atorvastatin, a generic version of Lipitor, is manufactured by Alkem Laboratories in India and was distributed nationwide in the US.
- Who
- Ascend Laboratories, in conjunction with the FDA
- What
- Recalled over 140,000 bottles of Atorvastatin
- When
- Recently (last month mentioned for FDA warning)
- Where
- Distributed nationwide in the US
- Why
- The drug failed to meet dissolution specifications, potentially making it less effective in lowering cholesterol and reducing the risk of heart attack and stroke.
- Drug Name
- Atorvastatin (generic Lipitor)
- Manufacturer
- Alkem Laboratories (India)
- Distributor
- Ascend Laboratories (New Jersey)
- Reason for Recall
- Failed dissolution specifications
- Number of Bottles Recalled
- Over 140,000
- Affected Batches Production Period
- November 2024 - September 2025